Source Post

Novo Nordisk ($NVO) In Trouble And Reddit ($RDDT) S&P 500

Aug 14, 2026

The creator discusses Novo Nordisk's recent earnings, noting that while they beat expectations, the bar was set very low. The company's pipeline for new drugs is seen as weak, and its sole focus on diabetes and obesity is a risk. The creator suggests diversification into areas like cancer research would be beneficial. The stock price fell significantly prior to earnings due to trial news but has seen a slight recovery.

Linked Mentions

Tickers discussed in this post

NOWNeutralLow ConvictionResearch Only

Service Now has become the third-largest position in the portfolio and is up 23%.

UNHNeutralLow ConvictionResearch Only

United Health Group has performed well, contributing to portfolio gains with an increase of almost 40%.

OSCRNeutralLow ConvictionResearch Only

Oscar is a significant contributor to the portfolio's performance, up 107%.

RDDTNeutralMedium ConvictionSignal-backedSecondary

Reddit's stock experienced a significant post-announcement jump due to its inclusion in the S&P 500, a move driven by index fund rebalancing rather than fundamentals.

LLYBullishHigh ConvictionSignal-backedPrimary

Eli Lilly is demonstrating strong performance with significant revenue growth driven by Mounjaro and Zepbound, and has increased its full-year guidance.

NVONeutralMedium ConvictionSignal-backedPrimary

Novo Nordisk's stock fell significantly due to trial news and a weak pipeline, despite beating low earnings expectations, and the company's narrow focus on diabetes/obesity presents a risk.

Linked Signals

Tracked calls opened from this post

LLY
buy opened Aug 14, 2026
-4.32%